A systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer

Is the Importance of Heart Dose Overstated in the Treatment of Non-Small Cell Lung Cancer? A Systematic Review of the Literature

(2019) Tina Wanting Zhang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial

(2019) David Ball et al.   LANCET ONCOLOGY

Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301)

(2018) Shinji Atagi et al.   Clinical Lung Cancer

A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

(2018) Jean-Paul Sculier et al.   LUNG CANCER

Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer

(2018) Ronan L. McDermott et al.   RADIOTHERAPY AND ONCOLOGY

A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L

(2018) Tomonari Sasaki et al.   BRITISH JOURNAL OF CANCER

The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)

(2018) Judi van Diessen et al.   RADIOTHERAPY AND ONCOLOGY

Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer

(2017) Robert T. Dess et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

(2017) Kyle Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

(2017) Stephen G. Chun et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839

(2017) Martin J. Edelman et al.   Journal of Thoracic Oncology

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer

(2017) Christina K. Speirs et al.   Journal of Thoracic Oncology

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60 Gy and 66 Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC

(2017) Olfred Hansen et al.   RADIOTHERAPY AND ONCOLOGY

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status

(2017) Youngjoo Lee et al.   Cancer Research and Treatment

Application of Guideline Recommended Treatment in Routine Clinical Practice: A Population-based Study of Stage I–IIIB Non-small Cell Lung Cancer

(2016) K.J. Duggan et al.   CLINICAL ONCOLOGY

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01

(2016) Pierre Fournel et al.   EUROPEAN JOURNAL OF CANCER

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2016) Suresh Senan et al.   JOURNAL OF CLINICAL ONCOLOGY

S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer

(2016) Junfei Feng et al.   MEDICINE

Acute esophagitis for patients with local–regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy

(2016) Yi Pan et al.   RADIOTHERAPY AND ONCOLOGY

Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation

(2016) Susan L. Tucker et al.   RADIOTHERAPY AND ONCOLOGY

SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC

(2016) Jan Nyman et al.   RADIOTHERAPY AND ONCOLOGY

A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients

(2015) Cary Oberije et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

(2015) Jeffrey D Bradley et al.   LANCET ONCOLOGY

International Patterns of Radiotherapy Practice for Non–Small Cell Lung Cancer

(2015) Shalini K. Vinod   SEMINARS IN RADIATION ONCOLOGY

Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology

(2014) A. G. Pallis et al.   ANNALS OF ONCOLOGY

Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

(2013) A. Carrato et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adverse Event Reporting in Cancer Clinical Trial Publications

(2013) Shanthi Sivendran et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

(2013) Sarah C. Darby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007

(2013) Sarah Walters et al.   THORAX

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)

(2012) Shinji Atagi et al.   LANCET ONCOLOGY

Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology

(2011) S. I. Jalal et al.   ANNALS OF ONCOLOGY

Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410

(2011) W. J. Curran et al.   JNCI-Journal of the National Cancer Institute

Benefits and Adverse Events Among Elderly Patients Receiving Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: Analysis of the Okayama Lung Cancer Study Group Trial 0007

(2011) Nagio Takigawa et al.   Journal of Thoracic Oncology

Radiation Dose–Volume Effects in the Lung

(2010) Lawrence B. Marks et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

(2010) Nobuyuki Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial

(2010) Charles Lu et al.   JNCI-Journal of the National Cancer Institute

Gaps in Optimal Care for Lung Cancer

(2010) Shalini K. Vinod et al.   Journal of Thoracic Oncology

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer

(2010) Benjamin Movsas et al.   Journal of Thoracic Oncology

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment: Results of a Randomized Phase II Study

(2010) Sergiusz Nawrocki et al.   Journal of Thoracic Oncology

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Development and External Validation of Prognostic Model for 2-Year Survival of Non–Small-Cell Lung Cancer Patients Treated With Chemoradiotherapy

(2008) Cary Dehing-Oberije et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

(2008) Nasser Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

(2008) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY